Author: Fatma Bağcı (Turkey)
Co-authors: Mehmet Yasin Teke
Purpose
To report the closure of full thickness macular hole (FMTH) following intravitreal bevacizumab treatment for cystoid macular edema due to the central retinal vein occlusion (CRVO), with a history of previously failed macular hole surgery.
Setting/Venue
Ulucanlar EyeTraining and Research Hospital, Retina Clinic, Ankara, Turkey
Methods
A 76-year-old male patient presented with decreased vision in his right eye. The best corrected visual acuity (BCVA) was counting fingers from 5 m and 0.8 logMAR on his right and left eye, respectively. Slit lamp examination revealed unremarkable anterior segment findings on his both eyes. On funduscopic examination, regular, oval-shaped defect was observed on the right macula. Fundus autofluorescence (FAF) image showed hyperautofluorescence at the defect region. OCT demonstrated FTMH with 425 μm in aperture diameter and the whole separation of posterior hyaloid (Stage IV) at the right macula. For the treatment of FTMH, a pars plana vitrectomy (PPV), removal of posterior cortical vitreous, ILM peeling at macula with endotamponade using C3F8 were performed as a current standard procedure. After surgery, face-down positioning was applied for one week. Nevertheless, the closure of FTMH was not achieved. The patient did not accept any surgical technique that has been proposed to treat a refractory FTMH. At the end of one year, the patient applied with more decreased vision on his right eye. BCVA was counting fingers from 1 m. On funduscopic examination of right eye, dilated tortuous veins, retinal hemorrhages at four quadrants and macular edema were observed.
Results
Based on precise evaluation of fundoscopic examination, FAF and OCT, central retinal vein occlusion was diagnosed. The patient underwent intravitreal bevacizumab injections for three consecutive months. At follow up, resolution of cystoid macular edema and serous macular detachment were observed. Unexpectedly, it is detected that refractive macular hole was closed and the foveal counter was almost built. FTMH has been treated currently with a standard procedure with the high closure rate. Failure was observed only in a small portion of FTMH, especially in larger and longstanding FTMH’s, referred as refractory FTMH. To treat a refractory FTMH, resent studies investigated many surgical techniques such as extending ILM peeling, surgically induced macular detachment, injection of blood components, insertion of autologous ILM flap, autologous lens capsule flap, neurosensory retinal autologous free flap, and amniotic membrane. Literature suggests different mechanisms to explain how a refractory FTMH closes. These include i) reducing the tangential tractional forces by enlarging ILM peeling ii) providing a scaffold for glial cell proliferation and migration by insertion of various tissues iii) allowing the edges of FTMH to come closer by surgically induction of macular detachment. On the other hand, there are limitations and some risks of each surgical approaches.
Conlusions
The closure of FTMH was observed following intravitreal bevacizumab treatment for cystoid macular edema due to the CRVO. It is fair to argue that the formation of CSME, as an innovative approach, may aid to closure of refractive FTMH by providing the hole edges to come closer. However, it remains tremendously unclear how to form CSME in patients with refractive FTMH, which requires further investigation.
Financial Disclosure
The authors received no financial support for the research, authorship, and/or publication of this report.
Comments
-